Alterity receives a $4.8 million R&D Tax Incentive Refund
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.8 million cash refund under the Australian Government’s R&D Tax Incentive Scheme.
The refund relates to the cost of eligible research and development activities conducted during the 2019 financial year. These funds will be used to further Alterity’s research and development activities.
The R&D Tax Incentive refund will add to Alterity’s cash reserves which was reported as A$10.7 million at the end of September 2019.
Authorisation & Additional information
This announcement was authorised by Geoffrey Kempler, CEO and Chairman of Alterity Therapeutics Limited.